UTAH MEDICAL PRODUCTS INC

For the period ended Dec 31, 2024. Filed Mar 26, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 26, 2025

UTMD$72.86-0.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Cash Flow

UTAH MEDICAL PRODUCTS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOW
Years Ended December 31, 2024, 2023 and 2022
(In thousands)
2024 · 2023 · 2022
Cash flows from operating activities:
Net income		$13,874		$16,635		$16,473
Adjustments to reconcile net income to net
cash provided by operating activities:
		Depreciation		730		623		612
		Amortization		2,065		5,692		6,417
		Provision for losses on accounts receivable		(4)		(33)		30
		Amortization of operating lease assets		51		53		53
		Deferred income taxes		(359)		(693)		(401)
		Stock-based compensation expense		256		225		183
		Tax benefit attributable to exercise of stock options		21		12		6
(Increase) decrease in:
			Accounts receivable		(835)		2,270		(511)
			Other receivables		54		0		(14)
			Inventories		587		(670)		(2,353)
			Prepaid expenses and other current assets		(32)		45		(64)
Increase (decrease) in:
			Accounts payable		(73)		(456)		464
			Accrued expenses		(1,504)		(1,422)		252
				Net cash provided by operating activities		14,831		22,281		21,147
Cash flows from investing activities:
Capital expenditures for:
		Property and equipment		(230)		(639)		(809)
		Intangible assets		(5)		-		(9)
		Proceeds from the sale of property and equipment		27		-		-
				Net cash (used in) investing activities		(208)		(639)		(818)
Cash flows from financing activities:
	Proceeds from issuance of common stock - options		390		117		174
	Common stock purchased and retired		(19,968)		-		(2,495)
	Dividends paid		(4,260)		(4,282)		(3,163)
				Net cash (used in) financing activities		(23,838)		(4,165)		(5,484)
Effect of exchange rate changes on cash		(677)		339		(767)
				Net increase in cash and cash equivalents		(9,892)		17,816		14,078
Cash at beginning of year		92,868		75,052		60,974
Cash at end of year		$82,976		$92,868		$75,052
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the year for:
	Income taxes		$4,638		$4,827		$4,970
Interest · - · - · -
See accompanying notes to financial statements.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.